Indoco Remedies rises on getting EIR from USFDA for API manufacturing facility at Patalganga

12 Dec 2025 Evaluate

Indoco Remedies is currently trading at Rs. 241.05, up by 1.65 points or 0.69% from its previous closing of Rs. 239.40 on the BSE.

The scrip opened at Rs. 240.00 and has touched a high and low of Rs. 251.05 and Rs. 239.25 respectively. So far 1433 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 348.60 on 17-Dec-2024 and a 52 week low of Rs. 190.00 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 254.70 and Rs. 236.05 respectively. The current market cap of the company is Rs. 2223.64 crore.

The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 19.41% and 21.69% respectively.

Indoco Remedies has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from September 15, 2025 to September 19, 2025.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

248.15 5.15 (2.12%)
15-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1280.40
Cipla 1507.25
Zydus Lifesciences 921.25
Lupin 2090.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×